PDSB

MKT CAP:$52M

PDS Biotechnology Corporation

Market Cap

$52M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$0.93+$0.09 (+11.39%)

Apr 23, 2026

Company Details

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first lin...

CEO

Frank K. Bedu-Addo

IPO Date

Sep 30, 2015

Website

www.pdsbiotech.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$35M

EPS (Diluted)

-$0.83

Free Cash Flow

-$32M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q4 2025

May 13, 2026

PENDING

Q3 2025

Nov 13, 2025

$0EPS -$0.19

Q2 2025

Aug 13, 2025

$0EPS -$0.21

Q1 2025

May 14, 2025

$0EPS -$0.21

FY 2024

Mar 27, 2025

$0EPS -$1.03

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$0	$0	-$6M
Q1 22	$0	$0	-$8M
Q2 22	$0	$0	-$7M
Q3 22	$0	$0	-$7M
Q4 22	$0	$0	-$19M
Q1 23	$0	$0	-$9M
Q2 23	$0	$0	-$13M
Q3 23	$0	$0	-$11M
Q4 23	$0	$0	-$10M
Q1 24	$0	$0	-$10M
Q2 24	$0	$0	-$9M
Q3 24	$0	$0	-$10M
Q4 24	$0	-$15.1K	-$7M
Q1 25	$0	$0	-$9M
Q2 25	$0	$0	-$8M
Q3 25	$0	$0	-$8M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$5M	-$5M
Q1 22	-$6M	-$6M
Q2 22	-$6M	-$6M
Q3 22	-$6M	-$6M
Q4 22	-$8M	-$8M
Q1 23	-$13M	-$13M
Q2 23	-$5M	-$5M
Q3 23	-$7M	-$7M
Q4 23	-$8M	-$8M
Q1 24	-$10M	-$10M
Q2 24	-$9M	-$9M
Q3 24	-$8M	-$8M
Q4 24	-$8M	-$8M
Q1 25	-$9M	-$9M
Q2 25	-$9M	-$9M
Q3 25	-$6M	-$6M

Capital Expenditures

Quarter	CapEx
Q4 21	$5
Q1 22	$1
Q2 22	$2
Q3 22	$4
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$29.0K
Q3 24	$1
Q4 24	$0
Q1 25	$0
Q2 25	$3
Q3 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	—	+57.0%
Q1 22	—	+178.1%
Q2 22	—	+38.9%
Q3 22	—	+4.6%
Q4 22	—	+197.7%
Q1 23	—	+11.1%
Q2 23	—	+79.0%
Q3 23	—	+44.5%
Q4 23	—	-44.7%
Q1 24	—	+7.2%
Q2 24	—	-31.6%
Q3 24	—	-3.2%
Q4 24	—	-29.3%
Q1 25	—	-9.8%
Q2 25	—	-12.2%
Q3 25	—	-20.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$0	—
Q1 22	$0	—
Q2 22	$0	—
Q3 22	$0	—
Q4 22	$1M	—
Q1 23	$2M	—
Q2 23	$2M	—
Q3 23	$2M	—
Q4 23	$1M	—
Q1 24	$2M	—
Q2 24	$2M	—
Q3 24	$2M	—
Q4 24	$2M	—
Q1 25	$1M	—
Q2 25	$0	—
Q3 25	$1M	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 21	$3M	$3M	—	—
Q1 22	$5M	$3M	—	—
Q2 22	$4M	$3M	—	—
Q3 22	$4M	$3M	—	—
Q4 22	$16M	$2M	$232.5K	—
Q1 23	$6M	$4M	—	—
Q2 23	$8M	$5M	—	—
Q3 23	$6M	$4M	—	—
Q4 23	$7M	$3M	$264.0K	—
Q1 24	$7M	$3M	—	—
Q2 24	$5M	$4M	—	—
Q3 24	$7M	$3M	—	—
Q4 24	$5M	—	—	$3M
Q1 25	$6M	$3M	—	—
Q2 25	$4M	$3M	—	—
Q3 25	$5M	—	—	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$59M	$0	$59M
Q2 22	$53M	$0	$53M
Q3 22	$72M	$0	$72M
Q4 22	$74M	$0	$74M
Q1 23	$65M	$0	$65M
Q2 23	$61M	$0	$61M
Q3 23	$54M	$0	$54M
Q4 23	$57M	$0	$57M
Q1 24	$67M	$0	$67M
Q2 24	$58M	$0	$58M
Q3 24	$50M	$0	$50M
Q4 24	$42M	$0	$42M
Q1 25	$40M	$0	$40M
Q2 25	$32M	$0	$32M
Q3 25	$26M	$0	$26M
Q4 25	$27M	$0	$27M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	28M	-0.0%	+27.5%
Q1 22	26M	-8.0%	+17.5%
Q2 22	28M	+8.8%	+22.8%
Q3 22	28M	+0.0%	+0.1%
Q4 22	29M	+1.1%	+1.2%
Q1 23	30M	+5.8%	+16.3%
Q2 23	31M	+1.2%	+8.3%
Q3 23	31M	+0.4%	+8.6%
Q4 23	32M	+2.5%	+10.1%
Q1 24	35M	+9.9%	+14.4%
Q2 24	37M	+5.4%	+19.1%
Q3 24	37M	+0.3%	+19.1%
Q4 24	36M	-1.0%	+15.1%
Q1 25	41M	+11.2%	+16.4%
Q2 25	46M	+13.3%	+25.1%
Q3 25	47M	+2.1%	+27.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$0	22
Q1 22	$0	22
Q2 22	$0	22
Q3 22	$0	22
Q4 22	$0	26
Q1 23	$0	26
Q2 23	$0	26
Q3 23	$0	26
Q4 23	$0	25
Q1 24	$0	25
Q2 24	$0	25
Q3 24	$0	25
Q4 24	$0	24
Q1 25	$0	24
Q2 25	$0	24
Q3 25	$0	24

Revenue / Employee